准备和评估以局部跨度为60的沃里可纳基油凝
Hiba Muneer Fysal1, Hanan Jalal Kassab2
1Ministry of Health, Baghdad, Iraq.
Journal of advanced pharmaceutical technology & research
|April 3, 2025
概括
这项研究开发了一种新的Voriconazole (VOR) oleogel用于局部皮肤真菌感染. 优化的配方表现出良好的药物释放和抗真菌活性,为口服和静脉注射治疗提供了一个有前途的替代方案.
科学领域:
- 制药科学 制药科学
- 皮肤病学 皮肤病学
- 菌类学 菌类学是指菌类学.
背景情况:
- 沃里科纳 (VOR) 是一种三醇抗真菌剂,对于治疗真菌感染至关重要.
- 口服和静脉注射VOR与显著的全身副作用有关.
- 需要局部药物输送系统来提高疗效并最大限度地减少不良影响.
研究的目的:
- 开发和描述一种用于局部应用的新型Voriconazole (VOR) 凝.
- 评估VOR油凝在治疗皮肤真菌感染方面的潜力.
- 为了克服与口服和IV VOR管理相关的全身副作用.
主要方法:
- 使用Span 60作为各种油 (油性油,葡萄,芝麻) 中的凝剂,制备VOR油凝.
- 确定最小凝度和对准备好的配方进行全面评估.
- 对优化配方的抗真菌活性,粘度,质感和药物释放特征的评估.
- 里埃变换红外光谱法 (FTIR) 用于研究药物辅助剂相互作用.
主要成果:
- 含有Span 60和芝麻油的优化配方 (14SSO) 表现出100%的药物释放.
- 优化的oleogel显示出对皮肤真菌病原体具有显著的抗真菌活性.
- 粘度研究显示伪塑料的剪切稀释行为,表明良好的扩散性.
- FTIR分析证实,沃里康纳和辅助剂之间没有显著的相互作用.
结论:
- 开发的Voriconazole oleogel (14SSO) 是一种稳定有效的局部配方.
- 这种油脂凝为治疗皮肤真菌感染提供了一个有前途的治疗方案.
- 局部VOR油凝可以潜在地减少与常规施用途径相关的全身副作用.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
Oral Drug Delivery Systems: Introduction
279
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
279
Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222
Ophthalmic Drug Delivery Systems
283
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
283
Antifungal Agents
119
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119


